Small cell lung cancer (SCLC) is characterized by rapid growth and high metastatic capacity.
It has strong epidemiologic and biologic links to tobacco carcinogens. Although the majority …

Small cell lung cancer (SCLC; accounting for approximately 13%–15% of all lung cancers)
is an exceptionally lethal malignancy characterized by rapid doubling time and high …

Small cell lung cancer (SCLC) is an aggressive malignancy that includes subtypes defined
by differential expression of ASCL1, NEUROD1, and POU2F3 (SCLC-A,-N, and-P …

Radiation therapy is a mainstay of cancer treatment but does not always lead to complete
tumor regression. Here we combine radiotherapy with blockade of the 'don't-eat-me'cell …

Malignant pleural mesothelioma (MPM) is an aggressive cancer with rising incidence and
challenging clinical management. Through a large series of whole-genome sequencing …

We performed comprehensive proteogenomic characterization of small cell lung cancer
(SCLC) using paired tumors and adjacent lung tissues from 112 treatment-naive patients …

The tissue distribution and prognostic relevance of subtype‐specific proteins (ASCL1,
NEUROD1, POU2F3, YAP1) present an evolving area of research in small‐cell lung cancer …

Small cell lung cancer (SCLC) is a rapidly growing, highly metastatic, and relatively immune-
cold lung cancer subtype. Historically viewed in the laboratory and clinic as a single …

Introduction SCLC is a highly aggressive neuroendocrine tumor that is characterized by
early acquired therapeutic resistance and modest benefit from immune checkpoint blockade …

Small cell lung cancer (SCLC) is the most aggressive subtype of lung cancer, accounting for
approximately 15% among all lung cancers. Despite the ability of chemotherapy, the first …